Aberrant expression of T-plastin in Sezary cells

Ming-wan Su1, Irene Dorocicz, Wieslawa H Dragowska

  • 1Chieng Genomics Centre, Laboratory of Predictive Medicine and Therapeutics, Vancouver Coastal Health Research Institute, Vancouver, British Columbia, V5Z 4E8 Canada.

Cancer Research
|November 13, 2003
PubMed

Insights

Researchers identified T-plastin as a potential specific marker for Sezary syndrome (SS), a rare cancer. This discovery could improve diagnosis and treatment for this cutaneous T-cell lymphoma.

Area of Science:

  • Hematology
  • Oncology
  • Dermatology

Background:

  • Mycosis fungoides (MF) and Sezary syndrome (SS) are the most common cutaneous T-cell lymphomas.
  • The exact nature and specific markers for MF/SS cancer cells remain unknown, complicating diagnosis and treatment.
  • Current understanding suggests a relation to mature T-helper cells, but definitive proof is lacking.

Purpose of the Study:

  • To identify specific molecular markers for Sezary cells in Sezary syndrome.
  • To investigate potential diagnostic and therapeutic targets for MF/SS.

Main Methods:

  • Global genomic screening using modified representational difference analysis on Sezary cells.
  • Analysis of T-plastin mRNA and protein expression in Sezary cells compared to healthy controls and patients with nonmalignant dermatoses.

Main Results:

  • Sezary cells from most Sezary syndrome patients aberrantly expressed T-plastin mRNA and protein.
  • T-plastin, a regulator of actin assembly and cellular motility, was detected in hematopoietic cells for the first time.
  • This aberrant expression was not observed in T-helper cells from healthy individuals or patients with nonmalignant dermatoses.

Conclusions:

  • T-plastin shows potential as a Sezary cell-specific marker.
  • This finding could significantly aid in the diagnosis and treatment of Sezary syndrome.
  • Further research into T-plastin's role may open new therapeutic avenues for cutaneous T-cell lymphomas.